From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease

Author(s): Jazmín Alarcón-Espósito*, Michael Mallea, Julio Rodríguez-Lavado*

Journal Name: Current Neuropharmacology

Volume 19 , Issue 6 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Alzheimer’s disease (AD) is a chronic, progressive, and fatal neurodegenerative disorder affecting cognition, behavior, and function, being one of the most common causes of mental deterioration in elderly people. Once thought as being just developed because of β amyloid depositions or neurofibrillary Tau tangles, during the last decades, numerous AD-related targets have been established, the multifactorial nature of AD became evident. In this context, the one drug-one target paradigm has resulted in being inefficient in facing AD and other disorders with complex etiology, opening the field for the emergence of the multitarget approach. In this review, we highlight the recent advances within this area, emphasizing in hybridization tools of well-known chemical scaffolds endowed with pharmacological properties concerning AD, such as curcumin-, resveratrol-, chromone- and indole-. We focus mainly on well established and incipient AD therapeutic targets, AChE, BuChE, MAOs, β-amyloid deposition, 5-HT4 and Serotonin transporter, with the aim to shed light about new insights in the AD multitarget therapy.

Keywords: Alzheimer disease, multi-target directed ligands, cholinesterase inhibitors, serotonin transporter, 5-HT receptors, β – amyloid aggregation, tau protein, monoamine oxidase.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 6
Year: 2021
Published on: 26 May, 2021
Page: [832 - 867]
Pages: 36
DOI: 10.2174/1570159X18666200914155951
Price: $65

Article Metrics

PDF: 33